Cost per response analysis of deucravacitinib versus apremilast and first-line biologics among patients with moderate to severe plaque psoriasis in the United States

• Main Authors: Sang Hee Park (Author), Mark Lambton (Author), Jordana Schmier (Author), Sara Hovland (Author), Keith Wittstock (Author), Vardhaman Patel (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background Understanding the economic value of deucravacitinib and apremilast could assist treatment decision-making for patients with moderate to severe plaque psoriasis.Objective This study compared the cost per response (CPR) for US patients initiating deucravacitinib versus apremilast for modera...